Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Xun Lai, MD, Jian-Qiong Liu, MD, Lujia Dong, MD, Hong-Mei Ou-Yang, PhD, Zi-Jin Dian, PhD, Jian-Xin Song, PhD, Ya-Xian Jiang, PhD, Xiang-Mei Yao, MD, Xue-Zhong Gu, MD, Xiao-Li Gao, MD, Ya-Yun Wu, MD, Lung-Ji Chang, PhD

Blood (2016) 128 (22): 1633.

https://doi.org/10.1182/blood.V128.22.1633.1633

Published: 2016

Journal Articles

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

Yan Xu, MDPhD, Shuhui Deng, MD, Gang An, MDPhD, Zengjun Li, Sr., Xiaoqi Qin, MD, Weiwei Sui, MD, Xiaoyan Feng, Dehui Zou, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 5394.

https://doi.org/10.1182/blood.V126.23.5394.5394

Published: 2015

Journal Articles

A Pilot Study of Vitamin D Repletion Shows Improvement in Pain and Vascular Endothelial Function in Adult Patients with Sickle Cell Disease

Mary K Lintel, BA, Latanya Bowman, BS, Xu Hongyan, PhD, Abdullah Kutlar, MD, Ryan A Harris, PhD, E. Leila Jerome Clay, MD

Blood (2015) 126 (23): 4589.

https://doi.org/10.1182/blood.V126.23.4589.4589

Published: 2015

Journal Articles

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Adam Nowicki, MD, Joanna Czerwinska-Rybak, MSc, Monika Joks, MD PhD, Tomasz Szczepaniak, MD PhD, Bochenek Maciej, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2015) 126 (23): 2986.

https://doi.org/10.1182/blood.V126.23.2986.2986

Published: 2015

Journal Articles

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MD MPH, Chandra Pooja, MD, Monica S Chatwal, Sungjin Kim, MS, Zhengjia Chen, PhD, Jeanne Kowalski, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 2525.

https://doi.org/10.1182/blood.V124.21.2525.2525

Published: 2014

Journal Articles

Age As an Independent Clinical Predictor for Vitamin D Deficiency in Sickle Cell Disease

Jin Han, PharmD, PhD, Santosh L. Saraf, MD, Taimur Abbasi, MD, Xu Zhang, PhD, Robert E. Molokie, MD, Johara Hassan, MD, Michel Gowhari, DO, Chaher Alhandalous, MD, Roberto F. Machado, MD, Victor R. Gordeuk, MD

Blood (2014) 124 (21): 1385.

https://doi.org/10.1182/blood.V124.21.1385.1385

Published: 2014

Journal Articles

Interventions to combat Vitamin D Deficiency in patients undergoing Hematopoietic Stem Cell Transplantation

Andrea Z Pereira, MDPhD, Silvia MF Piovacari, D, Fabiana Lucio, RD, Marcia Tanaka, RD, Ana Paula N Barrere, RD, Juliana Bernardo Silva, RD, Andreza Alice Feitosa Ribeiro, MD PhD, Nelson Hamerschlak, MD PhD

Blood (2014) 124 (21): 5996.

https://doi.org/10.1182/blood.V124.21.5996.5996

Published: 2014

Journal Articles

25-OH-Vitamin-D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Is Associated With An Inferior Outcome Of Elderly DLBCL Patients Treated With Rituximab

Joerg Thomas Bittenbring, Bettina Altmann, Frank Neumann, Marina Achenbach, Joerg Reichrath, Marita Ziepert, Juergen Geisel, Evi Regitz, Gerhard Held, Michael Pfreundschuh, MD Prof

Blood (2013) 122 (21): 1819.

https://doi.org/10.1182/blood.V122.21.1819.1819

Published: 2013

Journal Articles

Minimal Residual Disease Levels At Time Of CR1 and Transplant Predict Outcome In Philadelphia Chromosome-Negative Adult ALL

Mingming Zhang, PhD, Yi Luo, Xiaoyu Lai, Yamin Tan, Weiyan Zheng, M.D., Yuanyuan Zhu, Jimin Shi, He Huang, MD, PhD.

Blood (2013) 122 (21): 713.

https://doi.org/10.1182/blood.V122.21.713.713

Published: 2013

Journal Articles

Vitamin D Status and Its Correlation with Bone Mineral Density in Long Term Survivors After Childhood Hematopoietic Stem Cell Transplantation

Amy Garee, RN, MS, PNP, Micah Skeens, RN, MS, PNP, Sasigarn Bowden, MD, Manmohan Kamboj, MD, Sally Wildman, DO, BS, BA, Rajinder PS Bajwa, MBBS, MD, MRCP

Blood (2012) 120 (21): 4472.

https://doi.org/10.1182/blood.V120.21.4472.4472

Published: 2012

Journal Articles

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Melissa Alsina, MD, Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Leonel Ochoa, MD, Taiga Nishihori, MD, Daniel M Sullivan, MD, Binglin Yue, Jongphil Kim, PhD, William Dalton, PhD, MD

Blood (2012) 120 (21): 4071.

https://doi.org/10.1182/blood.V120.21.4071.4071

Published: 2012

Journal Articles

Proteomic Signature Predicting Achievement of Very Good Partial Response In Patients with Multiple Myeloma Based On Complementary Label-Free and iTRAQ Quantitative Proteome Analysis

Dominik Dytfeld, MD, PhD, Malathi Kandarpa, PhD, John R Strahler, PhD, Dattatreya Mellacheruvu, Suchitra Subramani, Stephanie J Kraftson, Lambert Ngoka, PhD, Alexey Nesvizhskii, PhD, Arun Sreekumar, PhD, Andrzej J Jakubowiak, MD, PhD

Blood (2010) 116 (21): 1902.

https://doi.org/10.1182/blood.V116.21.1902.1902

Published: 2010

Journal Articles

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Luke F. Peterson, PhD, Diane Giannola, Kandarpa Malathi, Ph.D., Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2010) 116 (21): 3005.

https://doi.org/10.1182/blood.V116.21.3005.3005

Published: 2010

Journal Articles

Bortezomib and High-Dose Melphalan as a Novel Conditioning Regimen for Patients with POEMS Syndrome Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

XiaoWen Tang, MD, Xiaolan Shi, Xiaohui Hu, Shengli Xue, Huiying Qiu, Yue Han, Lingzhi Yan, Huifen Zhou, Yuejun Liu, Bin Gu, Aining Sun, Wu Depei, MD, PhD

Blood (2010) 116 (21): 4599.

https://doi.org/10.1182/blood.V116.21.4599.4599

Published: 2010

Journal Articles

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.

Blood (2009) 114 (22): 132.

https://doi.org/10.1182/blood.V114.22.132.132

Published: 2009

Journal Articles

Successful Bortezomib-Based Therapy in POEMS Syndrome.

Xiaowen Tang, Xiaolan Shi, Aining Sun, Huiying Qiu, Bin Gu, Huifen Zhou, Shengli Xue, Yuejun Liu, Changgeng Ruan, Wu Depei

Blood (2009) 114 (22): 4966.

https://doi.org/10.1182/blood.V114.22.4966.4966

Published: 2009

Journal Articles

Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.

Melissa Alsina, MD, Rachid Baz, MD, Jose L Ochoa, MD, Jyotishankar Raychaudhuri, Kara Kosakowski, Michelle Mintz, Kendra Anderson, William S Dalton, M.D., Ph.D, Daniel Sullivan

Blood (2009) 114 (22): 617.

https://doi.org/10.1182/blood.V114.22.617.617

Published: 2009

Journal Articles

Proteomic Profiling of Multiple Myeloma Using iTRAQ Labeling Followed by Multidimensional Liquid Chromatography and Tandem Mass Spectrometry.

Dominik Dytfeld, MD, PhD, Malathi Hari, PhD, John Strahler, PhD, Dattatreya Mellacheruvu, Suchitra Subramani, Alexey Nesvizhskii, PhD, Arun Sreekumar, PhD, Andrzej J Jakubowiak, MD, PhD

Blood (2009) 114 (22): 4865.

https://doi.org/10.1182/blood.V114.22.4865.4865

Published: 2009

Journal Articles

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Tara Kendall, PA, Ammar Al-Zoubi, MD, Yasser Khaled, MD, Shin Mineishi, MD, Christine Brozo, Erica Campagnaro, MD, Moshe Talpaz, Mark S. Kaminski, MD

Blood (2008) 112 (11): 3713.

https://doi.org/10.1182/blood.V112.11.3713.3713

Published: 2008

Journal Articles

Acute Lymphoblastic Leukemia with Mature Appearing Lymphocytes: First Chinese Case Report and Literature Review

QiGuo Zhang, Jian Ouyang, Jianyong Li, MD, PhD

Blood (2008) 112 (11): 4896.

https://doi.org/10.1182/blood.V112.11.4896.4896

Published: 2008

NARROW

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

A Pilot Study of Vitamin D Repletion Shows Improvement in Pain and Vascular Endothelial Function in Adult Patients with Sickle Cell Disease

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Age As an Independent Clinical Predictor for Vitamin D Deficiency in Sickle Cell Disease

Interventions to combat Vitamin D Deficiency in patients undergoing Hematopoietic Stem Cell Transplantation

25-OH-Vitamin-D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Is Associated With An Inferior Outcome Of Elderly DLBCL Patients Treated With Rituximab

Minimal Residual Disease Levels At Time Of CR1 and Transplant Predict Outcome In Philadelphia Chromosome-Negative Adult ALL

Vitamin D Status and Its Correlation with Bone Mineral Density in Long Term Survivors After Childhood Hematopoietic Stem Cell Transplantation

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Proteomic Signature Predicting Achievement of Very Good Partial Response In Patients with Multiple Myeloma Based On Complementary Label-Free and iTRAQ Quantitative Proteome Analysis

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Bortezomib and High-Dose Melphalan as a Novel Conditioning Regimen for Patients with POEMS Syndrome Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.

Successful Bortezomib-Based Therapy in POEMS Syndrome.

Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.

Proteomic Profiling of Multiple Myeloma Using iTRAQ Labeling Followed by Multidimensional Liquid Chromatography and Tandem Mass Spectrometry.

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Acute Lymphoblastic Leukemia with Mature Appearing Lymphocytes: First Chinese Case Report and Literature Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only